These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 7875530

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE, Hallam TJ, Brown AM, Boyfield I, Cooper DG, Hickey DM, Jaxa-Chamiec AA, Kaumann AJ, Keen M, Kelly E.
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [Abstract] [Full Text] [Related]

  • 25. Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations.
    Anfossi G, Massucco P, Mattiello L, Piretto V, Mularoni E, Cavalot F, Paoletti G, Trovati M.
    Thromb Res; 1996 Apr 01; 82(1):57-68. PubMed ID: 8731510
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner.
    Ok WJ, Cho HJ, Kim HH, Lee DH, Kang HY, Kwon HW, Rhee MH, Kim M, Park HJ.
    J Atheroscler Thromb; 2012 Apr 01; 19(4):337-48. PubMed ID: 22498765
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
    Nagakura N, Saeki T, Harada K, Yoshitake S, Kobayashi S, Yamanaka T, Saito I.
    Biol Pharm Bull; 1996 Jun 01; 19(6):828-33. PubMed ID: 8799481
    [Abstract] [Full Text] [Related]

  • 36. Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
    Ferreira MA, do Nascimento NR, de Sousa CM, Pessoa OD, de Lemos TL, Ventura JS, Schattner M, Chudzinski-Tavassi AM.
    Br J Pharmacol; 2008 Jul 01; 154(6):1216-24. PubMed ID: 18516074
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents.
    Russo I, Doronzo G, Mattiello L, De Salve A, Trovati M, Anfossi G.
    Thromb Res; 2004 Jul 01; 114(4):265-73. PubMed ID: 15381390
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.